|Biotech partner:||EndoCeutics (Canada)|
|Pharma Partner:||Bayer Schering Pharma (Germany)|
|Type of agreement:||* licensing
* commercialization/ distribution
* marketing/ promotion
|Compound:||Vaginorm® (intra-vaginal application of dehydroepiandrosterone-DHEA)|
|Disease area:||vulvovaginal atrophy and female sexual dysfunction in postmenopausal women|
|Development phase:||A Phase III clinical program for Vaginorm in the treatment of symptoms of vulvovaginal atrophy and female sexual dysfunction in postmenopausal women has been initiated.|
|Nature of the agreement:||Bayer Schering Pharma has signed a global exclusive cooperation agreement with the Canadian company EndoCeutics for the development and commercialization of Vaginorm®, an intra-vaginal application of dehydroepiandrosterone (DHEA).
EndoCeutics is responsible for conducting the Phase III studies for Vaginorm®. Thereafter, Bayer will be responsible for its registration and commercialization. Under the terms of the agreement, EndoCeutics grants Bayer a worldwide, exclusive license to develop, manufacture and commercialize Vaginorm®.
|Financial terms of the agreement:||Financial details were not disclosed.|